The Science Journal of the Lander
College of Arts and Sciences
Volume 8
Number 1 Fall 2014
1-1-2014

PARP Inhibition: A Method of Treating and Preventing Certain
Cancers
Chana Tropper
Touro College

Follow this and additional works at: https://touroscholar.touro.edu/sjlcas
Part of the Medical Genetics Commons, and the Neoplasms Commons

Recommended Citation
Tropper, C. (2014). PARP Inhibition: A Method of Treating and Preventing Certain Cancers. The Science
Journal of the Lander College of Arts and Sciences, 8(1). Retrieved from https://touroscholar.touro.edu/
sjlcas/vol8/iss1/3

This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar.
It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an
authorized editor of Touro Scholar. For more information, please contact touro.scholar@touro.edu.

-

PARP Inhibition: A Method of Treating and
Preventing Certain Cancers
By: Chana Tropper

Chana will graduate July 2015 with a B.S. in biology. Chana is currently
in a program for Radiation Therapy at Memorial Sloan Kettering Cancer Center.

Abstract
Breast cancer is one of the largest causes of cancer related deaths in women. Less than 5% of breast cancer
cases are genetically inherited and most often develop after menopause. The BRCA gene mutation is a genetic
inheritance which increases ones chances of developing breast cancer at a young age tenfold. Recent research
has proposed a method of treatment in genetically inherited breast cancers by taking advantage of the impaired
DNA repair pathway caused by the BRCA mutation. The combination of a BRCA mutation, which leads to
deficient double strand DNA repair, and PARP inhibition, which leads to deficient single strand DNA repair, has
proven to be synthetically lethal to tumor cells. Clinical trials are determining if this method should be used as
a mono-treatment or as an enhancer to other treatment options. Research has also shown that PARP inhibition
may be extended to non-genetic cancers as well by targeting similar proteins involved in DNA repair and cell
cycle regulation. The most effective inhibitors, their dosages, and side effects are still being studied in clinical trials.
The purpose of this paper is to determine the most effective way to take advantage of the synthetically lethal
relationship between PARP inhibition and DNA damage repair deficiencies.
Introduction

Damage to DNA happens on a regular basis due to normal metabolism mishaps and external triggers. DNA breaks are categorized
into two types: double strand and single strand. The healthy body
has DNA repair pathways in place to repair both kinds of breaks.
Both the Homologous Repair pathway and the Non-homologous
End Joining repair pathway work to repair double strand breaks.
The Base Excision repair pathway repairs single strand breaks. As
long as there is damaged DNA in a cell, the cycle should be stopped,
preventing the cell from dividing. If the damage cannot be repaired,
the cell has systems in place to initiate apoptosis. This paper explores the possibility of taking advantage of the systems in place to
initiate apoptosis as a method of killing out tumorous cells.

Methods

The Touro database and PubMed.gov were used to find articles
and original research regarding PARP inhibition in genetic cancers
as well as cancers resulting from Homologous Recombination deficiencies. Articles referenced in the articles found on the above
mentioned databases were used as well.

Double Strand Break Repair Pathways

Although both the Homologous Recombination (HR) and Nonhomologous End Joining (NHEJ) repair pathways work to repair
double strand breaks, the HR repair pathway is a much more
reliable pathway. The HR pathway uses a sister chromatid as a
template to repair the damage, which allows the repair to be extremely precise. Because sister chromatids are only available in
the S and G2 phases of the cell cycle, HR occurs at those points
in the cycle. NHEJ is a less complex process which does not require a template; the two broken ends are joined by ligation, a less
precise process which often results in insertion or deletion of
nucleotides (Murphy, 2010). (Figure 1)
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Figure1
Homologous recombination repair: A DNA lesion is recognized by the
MRN (MRE11–RAD50–NBS1) complex, which is recruited to the DSB to
generate single-stranded DNA by resection (see the figure; right panel). The
single-stranded ends are bound by replication protein A (RPA), RAD51 and
RAD52 and can subsequently invade the homologous template, creating
a D-loop and a Holliday junction, to prime DNA synthesis and to copy and
ultimately restore genetic information that was disrupted by the DSB.
HR: Homologous Recombination, NHEJ: Non-homologous End Joining

The BRCA Gene: A Tumor Suppressor

The BRCA gene functions as a tumor suppressor gene, a category of genes which repress the cell cycle and promote apoptosis.
Tumor suppressor genes are in place to prevent damaged DNA
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from replicating and integrating into the genome. The most established role of the BRCA gene is its regulation of the Homologous
Repair pathway. Cells with mutations in the BRCA gene thus lead
the cell along the more error prone NHEJ pathway, causing an
accumulation of chromosomal abnormalities and instability, which
contributes to tumorigenesis. Mutations in the BRCA gene have
been shown to cause a significant increase in the probability of
developing tumors of the breast and ovaries. Breast cancer resulting from a BRCA mutation, however, is unique in the sense
that only the tumor cells are deficient in the HR repair pathway.
Healthy cells have fully responsive repair pathways. This allows
treatment targeting this deficiency to be specific only to tumor
cells (Murphy, 2010).

The Role of the PARP Enzyme in Single
Strand Repair
The PARP enzymes’ main function is to initiate the Base Excision
Repair pathway by recruiting specific proteins to the site of single
strand DNA breaks; once the proteins are recruited, the PARPs
are released and the resultant protein complex does the actual
repair work. After initially binding to the DNA using its zinc finger domains, the PARP begins to transfer ADP ribose units from
NAD+ to a variety of acceptor proteins, thus creating a negative
charge which recruits the enzymes necessary for base excision

repair (Drew, Calvert, 2008). PARP inhibitors work either by trapping the PARP on the DNA, preventing the protein complex from
beginning its repair work, or by actually inhibiting the enzymatic
activity. Without PARP to initiate the Base Excision Repair process, the single strand breaks accumulate and eventually develop
into double strand breaks. (Figure 2)

Inhibition of the PARP Enzyme in BRCA
Deficient cells is Synthetically Lethal
Inhibition of PARP causes an increase in DNA single strand breaks,
which eventually evolve into double strand breaks at the site of
the original damage. Cells with a functional BRCA network can
respond to the inhibition of PARP through the use of the double
strand repair pathways. Cells with deficient BRCA genes, however,
are unable to properly respond to inhibition of PARP, leaving the
double strand breaks without a reliable repair method, causing
the two deficiencies to become a synthetically lethal combination
(Warrener, et al., 2012). Synthetic lethality is a condition by which
deletion or inactivation of only one of two genes would not cause
cell death, but deletion or inactivation of both of them is lethal
(Reinbolt, 2013). Thus, the inhibition of PARP in healthy cells is not
necessarily lethal because the double strand break repair pathways
can kick in to repair the damage. When paired with homologous
repair deficiencies, however, the inhibition of PARP has proven to

Figure 2:
PARP: Poly-ADP Ribose Polymerase 									

(intechopen.com)
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be lethal, because there are no efficient repair pathways for single
or double strand damage. With no repair pathways in place, the
cell is unable to maintain a stable cell cycle and should eventually undergo apoptosis. Inhibition of the PARP enzyme in tumor
cells resulting from homologous repair deficiencies inhibits single
strand repair mechanisms, initiating a selectively lethal response
in the tumor cells, allowing for effective and targeted treatment.

Proteins Involved in the HR Pathway

Homologous recombination is a pathway which involves many different proteins. Identifying the roles these proteins play is a possible way of determining a biomarker to predict if tumor cells will
respond to PARP inhibition. RAD51 is a protein which has been
found to co-localize with BRCA2, which is suggestive of the interconnected roles they each play in homologous recombination.The
HR pathway is initiated in either the S or G2 phases of the cell
cycle by a double strand break. The broken ends then need to be
resected to expose 3’ single stranded DNA tails, which need to
be loaded with RAD51 in order to invade the identical homologous strand of the sister chromatid and form new identical DNA
(Golmard, et al., 2013). BRCA2 has been shown to have binding
sites for both DNA and RAD51 and thus facilitates the localization and binding of RAD51 to the single strand DNA. Without
the aid of BRCA2, the RAD51 is unable to bind to the DNA and
the HR repair is unable to proceed (Murphy, 2010). BRCA1 is also
involved in initiating double strand repair by playing an active role
in resecting the broken DNA.
Cyclin-dependent kinases serve as regulators of the HR pathway

Figure 4:
					

through their roles in phosphorylation. They can phosphorylate
BRCA2 at the RAD51 binding domain and thereby block the binding of DNA and RAD51. This decreases the rate of HR, and is
meant to occur when the cell is exiting the G2 phase of the cycle,
and HR can no longer occur. They also phosphorylate the protein
CtIP, causing it to bind to a BRCA1 domain, which then becomes
activated and is responsible for the resection of the broken strand
of DNA to expose a 3’ tail, initiating the entire HR pathway. Cells

Figure 3:
HR: Homologous Repair, BER: Base Excision Repair					
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without CtIP have been shown to have defects in the HR pathway,
which is indicative of the involved role it plays in Homologous
Recombination (Murphy, 2010).
ATM is a kinase involved in phosphorylating many proteins involved in DNA repair and cell cycle check points. Cell cycle
checkpoints are in place to ensure that there is no damaged DNA
before the cell moves into the next phase. (Dujka, et al., 2010)
Studies have been done to determine if lack of ATM induces sensitivity to PARP inhibition, due to the lack of yet another DNA
repair mechanism. ATM was genetically repressed in breast cancer
cells which were then treated with Olaparib, a PARP inhibitor.The
results were compared with a control group of breast cancer cells
with active ATM. The control group cells got stuck at the G2/M
checkpoint, but only the ATM depleted cells actually initiated
apoptosis (Mantani, et al., 2013). These results indicate that ATM
deficiency is not necessary for response to PARP inhibition but it
does enhance the overall response greatly. Deactivating ATM in
a cell is a possible way of increasing the response it will have to
PARP inhibition.
P53 is a tumor suppressor protein which is activated in response
to DNA damage. P53 is normally held inactive by the mdm2 complex, which it is bound to. In response to DNA damage, p53 disassociates from mdm2, and binds to the damaged DNA (Clegg,
et al., 2012). Once activated, p53 activates p21, which then inhibits CDK2, a complex important in transitioning in the cell cycle
(Zhao, et al., 2012). The cell cycle is then stopped, giving time for
the proper repair proteins to be recruited to repair the damage. If
the damage is repaired, then p53 is deactivated and the cell cycle
continues. If the damage cannot be repaired, p53 initiates apoptosis. It has been found that p53 is somewhat regulated by the
BRCA gene, implying that a mutation in BRCA will cause a similar
deficiency in p53 (Murphy, 2010). This correlation explains why
BRCA mutated cells are prone to becoming tumorous; the tumor
suppression system regulated by p53 is not fully responsive, and
is unable to properly respond to the unrepaired DNA damage.

Proteins as a Biomarker to Determine
Sensitivity to PARP Inhibition
Identifying if cells are deficient in proteins involved in HR, such as
RAD51, CtIP, ATM, CDK’s and P53 can be a method of determining if a tumorous cell will respond to PARP inhibition. In addition,
inducing mutations in these proteins and other proteins involved
in DNA repair can be a way to prompt sensitivity to PARP inhibition, even in cells that are not necessarily deficient in BRCA
(Reinbolt, 2013).

Discussions

Trial experiments have been done to study the most effective way
to take advantage of the synthetically lethal relationship between

PARP inhibition and BRCA gene mutations. Different inhibitors
have been identified and tested in varying doses. Various side effects have been identified, and the timing of the therapy has been
experimented with. It is questionable whether to use PARP inhibition as a single agent or as an enhancing agent to other treatment
options.
PARP inhibition has been shown to enhance the effects of DNA
damaging agents, such as ionizing radiation and chemotherapy
.The principle driving the success of radiation therapy, for example, is that oxidizing free radicals are induced to produce single
and double strand breaks, prompting the tumorous cells to initiate apoptosis. (Abolfath, 2013) The role PARP plays in repairing
DNA damage is a potential resistance mechanism to the desired
effect of the radiation. Thus inhibition of the PARP enzymes is not
only allowing the radiation to produce the desired results, but it
enhances the effects by creating even more breaks (Basu, et al.,
2012).

Zinc deficiency and arsenic as potential PARP
inhibitors
The zinc finger domains on PARP are what allow it to bind to
DNA, beginning the whole Base Excision Repair process. Without
being bound to DNA, PARP is essentially useless.Thus a deficiency
in zinc ultimately leads to PARP inhibition due to the resultant
inability of the PARP to bind to DNA. Research has also shown
that arsenic can bind to the zinc finger domain in place of zinc,
which changes the zinc finger structure, also preventing it from
binding to DNA and causing it to lose all functionality (Sun, et al.,
2014). Practically, zinc levels can play a dual role: they are a possible biomarker to determine cell sensitivity to PARP inhibition
and depletion of the metal is a method of inducing the inhibition.
Arsenic, as well, although via a different mechanism than the others, is considered to be a PARP inhibitor.

Olaparib as a monotherapy in BRCA1/2
mutation associated breast cancers
In a study done in 2008, Olaparib, a PARP inhibitor taken orally,
was administered to a group of women all possessing mutations in
BRCA1 or BRCA2 genes. Olaparib was taken as a monotherapy,
but all the patients had been given at least one chemotherapy
regimen earlier. The study had 2 cohorts, the first was 400 mg
of Olaparib, which was established to be the maximum tolerable dose, taken twice daily. The second was 100 mg of Olaparib,
also taken twice daily. Both study schedules lasted for 168 days.
In the first cohort, 41% of the patients achieved the objective response, with 4% achieving a complete response and 37% achieving
a partial response. Forty four percent still had stable disease and
15% had progressive disease. The second cohort had only 22%
who achieved the objective response, with no patients achieving a
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complete response. Forty four percent still had stable disease and
33% had progressive disease (Tutt, et al., 2010). The results of this
trial show definite response of tumor cells to Olaparib.The higher
dosage produced better results compared to the lower dosage,
implying an enhanced response when the dosage is raised.

Olaparib in combination with Paclitaxel

Triple negative breast cancer, TNBC, is defined by lack of receptors for estrogen, progesterone, and human epithelial growth
factor, and responds to few treatment options. TNBC has been
shown to share similarities with BRCA1 associated breast cancers, (Nowsheen, et al., 2012) and a study was done in TNBC patients to determine the effect of combining PARP inhibition with
Paclitaxel, a chemotherapy agent which stabilizes microtubules.
The combined effect should prevent them from breaking down
during cell division, causing the cell cycle to be stopped and apoptosis to be initiated. Patients received 200 mg of Olaparib twice
daily and 90 mg of paclitaxel once a week for 6-10 28 day cycles.
There was a greater than expected occurrence of neutropenia,
a decrease in neutrophils which are responsible for destroying
bacteria, within the first two cycles, a side effect also found in
other studies done testing the combination of PARP inhibition
with chemotherapy agents. Neutropenia is common side effect
of Paclitaxel, but its occurrence increased significantly when combined with PARP inhibition. At the point which patients were experiencing neutropenia of grade 2 or higher, PARP inhibition was
maintained, Paclitaxel administration was stopped and G-CSF was
administered until the absolute neutrophil count (ANC) went up.
If the absolute neutrophil count went up, Paclitaxel was continued, if it did not paclitaxel was discontinued. Although the rate
of neutropenia occurrence increased, up to 40% of patients in
the study showed partial response to the combined treatment,
a greater response than has been seen with either treatment on
its own (Dent, et al., 2013). Research is being done to understand
the molecular reasoning of the increased neutropenia occurrence.
Studies are also determining the best treatment schedule to minimize the side effects and maximize results.

Niraparib as a monotherapy in BRCA
mutation carriers and sporadic cancers
Niraparib is also an oral PARP inhibitor and it has been studied as a
monotherapy not only in carriers of the BRCA mutation carriers,
but in patients with sporadic high grade serous ovarian cancer as
well, which has a high prevalence of Homologous Recombination
dysfunction. The study experimented with escalating doses to
determine the maximum tolerable dose, which was found to be
300 mg, taken twice daily. Thrombocytopenia and neutropenia
presented as side effects but were easily controlled with dose
reductions. Results of this study showed that greater response
was seen in cells sensitive to platinum, a common base in chemotherapy agents, as opposed to platinum resistant cells. There was
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some response seen in platinum resistant cells, however, implying
that the resistance mechanisms for PARP inhibition and platinum
do not entirely overlap (Sandhu, et al., 2013).
The results of the above studies demonstrate the existence of a
relationship between DNA damaging agents, such as chemotherapy, and PARP inhibition. They also establish that PARP inhibition is
not only effective in genetic tumors, but in other cancers involving
homologous repair deficiencies. The relationship between PARP
inhibition and platinum is logical, as they share a common goal of
inducing DNA damage. The mechanisms of action, however, are
clearly not the same because even the platinum resistant cells
showed a response to PARP inhibition. Further understanding of
the differences between the two and their resistance mechanisms
must be understood in order to maximize the positive effect PARP
inhibition can have on platinum resistant tumors. The response
shown by the sporadic tumor cells shows promise in expanding
PARP inhibition to include not only genetic cancers, but other
cancers resulting from HR deficiencies. The key will be in finding a
biomarker to determine which cells will respond positively.

Interferon Gamma as an enhancer of PARP
inhibition
Because of the role they play in tumor suppression and cell cycle
regulation, a study was done to determine if the interferon pathway is affected by or involved in the synthetically lethal combination of PARP inhibition and BRCA gene mutations. The interferon
pathway is a crucial response of the immune system to viruses,
bacteria, and tumor cells. Interferons are proteins which have
various functions, including regulation of the cell cycle, anti-viral
responses, and apoptosis. Studies have suggested that interferons
serve as regulators of the P53 gene, which is involved in the initiation of apoptosis (Takaoka, et al., 2003). H2AX is a gene which
codes for the histone H2A, around which DNA gets wrapped,
allowing for organized nucleosome formation. ATM is involved in
the phosphorylation of H2A as a reaction to DNA double strand
breaks in order to create space for the recruitment of repair proteins. Some of the interferons involved in cell cycle regulation and
apoptosis are activated via an ATM dependent pathway, suggesting
that an interconnected relationship exists between ATM, H2A, interferons, P53, and PARP (Warrener, et al., 2012).
The above-mentioned study took BRCA silenced cells and studied the effect of PARP inhibition on interferon pathway activation.
The PARP inhibited cells showed a three-fold increase in H2A
phosphorylation, which is indicative of the increase in double
strand breaks which results from the unrepaired single strand
breaks. Enhanced activation of the interferon pathway was shown
to correspond with the level of response to PARP inhibition, suggesting that the role the pathway plays in promoting apoptosis
serves as an enhancer to the effects of PARP inhibition. The study
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also determined that when interferon gamma was administered
together with the PARP inhibitors, the lethal response increased
ten-fold, verifying the involvement of the interferon pathway
in initiating apoptosis in PARP inhibited BRCA deficient cells
(Warrener, et al., 2012).
Because of the role it plays in initiating double strand break repair,
ATM depletion is another possible enhancer of PARP inhibition.
When ATM is not active, H2A cannot be phosphorylated, which
slows the response of the double strand break repair proteins.
A decreased double strand repair response leads to more unrepaired double strand breaks with no method of repairing themselves, thus increasing the amount of cells with sensitivity to PARP
inhibition. This relationship was proven in a study which showed
increased activation of the interferon pathway in ATM deficient
cells, confirming both the dependency of successful PARP inhibition on lack of proper double strand repair mechanisms and the
involvement of the interferon pathway in the apoptosis of PARP
inhibited BRCA deficient cells (Warrener, et al., 2012).

Possible Resistance Mechanisms to
PARP Inhibition
BRCA2 mutated cells have been found to develop resistance to
platinum based chemotherapy due to the development of a secondary mutation which corrects the original mutation, restoring
BRCA function (Wiedemeyer, et al., 2014). Cells harboring this
resistance will also display resistance to PARP inhibition, whose
success is dependent on a defective Homologous Recombination
deficiency. Not all platinum resistant tumor cells, however, develop as a result of the secondary mutation; those cells are still expected to retain sensitivity to PARP inhibition (Weil, Chen, 2011).
P-gp, P-glycoprotein, is a protein of the cell membrane coded for
by the ABCB1 gene that acts as a pump, pumping out foreign substances. This protein is involved in developing drug resistance, and
has been shown to be the cause of resistance to some anti-cancer drugs. Up-regulation of the ABCB1 gene has been proven to
demonstrate resistance to PARP inhibition due to the increased
presence of P-gp. This resistance, however, has been counteracted
with the administration of Tariquidar, a P-glycoprotein inhibitor
(Weil, Chen, 2011).
53BP1 is a protein attached to DNA which is replaced by BRCA1
during DNA damage repair. If 53BP1 is not replaced by BRCA1,
the HR pathway becomes inhibited. If 53BP1 is absent in a cell,
even in the case of a BRCA mutation, HR is still able to proceed
because there is no 53BP1 which needs to be displaced. Only
when 53BP1 is present and there is a BRCA mutation is HR actually impaired. An absence of 53BP1, therefore, is a possible resistance mechanism to PARP inhibition, through its restoration of
the HR pathway (Weil, Chen, 2011).

PARP inhibition as a proactive
treatment option
Until recently, BRCA1/BRCA2 mutation carriers have been faced
with the disheartening knowledge that they will most likely develop breast or ovarian cancer and the only proven preventative
measure to be taken was prophylactic surgery. The evolution of
PARP inhibition as a treatment option also introduces the possibility of using PARP inhibition as a chemo-preventative measure
for BRCA carriers who did not yet develop cancer, a much less
drastic measure than prophylactic surgery. There have not been
any conclusive studies done regarding using PARP inhibition as a
preventative treatment, but the same mechanism it uses to selectively kill tumor cells has been proposed as a way of preventing
them from developing in the first place.Tumor cells resulting from
BRCA deficiencies are the result of genetic alterations and defective DNA repair. Pre-exposing a BRCA mutation carrier to PARP
inhibitors is a proposed method of killing the genetically altered
cells, preventing them from developing into full blown tumors. It
has also been proposed to use PARP inhibition as a means of
preventing relapse, but no conclusive studies have been done at
this point to investigate the possibility of success in this approach.
Eventualities which must be considered in using PARP inhibition
as a long term treatment option are the side effects as well as the
danger in maintaining a defective repair pathway long term, especially in already high risk patients (Vinayek, Ford, 2010).

Conclusions

PARP inhibition shows promise on many different levels. The
main factors to bear in mind in the development of treatment
options are the specific target of only tumorous cells and minimal
side effects, both of which are realized in PARP inhibition. The
success of PARP inhibition expanded from genetically inherited
breast cancers to other cancers resulting from DNA damage
repair defects was demonstrated in clinical trials, which expands
the network of patients eligible for treatment, making it easier
to maintain the funding of research. PARP inhibition has elicited
positive responses both as a mono-therapy and as an enhancer
of other DNA damaging agents, such as chemotherapy and radiation. The proteins involved in Homologous Recombination show
great promise in functioning as predictive biomarkers of sensitivity
to PARP inhibition. Further understanding of the roles they play
will enable mutations of those proteins to be a method of inducing and/or enhancing sensitivity to PARP inhibition. The hope
that PARP inhibition presents not only as a treatment option but
also as a precautionary alternative to prophylactic surgery makes
the investment needed to make it a reality most worthwhile.
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Abbreviations
PARP
HR
NHEJ
BER
ATM

Poly ADP-ribose polymerase
Homologous Recombination
Non-homologous End Joining
Base Excision Repair
Ataxia Telangiectasia Mutated
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